PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Robust New Technology Platforms Aid the Search for Cancer Vaccines - Although the cancer vaccine industry has remained historically undervalued due to its failures, optimism surrounds the industry as proponents of this technology have persistently pursued investigations to demonstrate the clinical efficacy of cancer vaccin
Robust New Technology Platforms Aid the Search for Cancer Vaccines

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2008/02/22 - Although the cancer vaccine industry has remained historically undervalued due to its failures, optimism surrounds the industry as proponents of this technology have persistently pursued investigations to demonstrate the clinical efficacy of cancer vaccin.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cancer vaccines hold the potential to treat patients at an earlier stage of the disease, which sequentially generates therapies that will benefit the subset of population. In a metastatic disease setting, the trend would employ a cancer vaccine as an adjunct therapy with classical therapies such as chemotherapy, radiation therapy, and even with emerging therapies such as targeted therapies.

New analysis from Frost & Sullivan (technicalinsights.frost.com), Developments in Cancer Vaccine Industry, the evolution of cancer vaccine science holds claim to the most significant trend today; to a point where robust technology platforms to develop vaccines suitable for cancer exist. With many products in lead stages of clinical evaluation (phase III), the cancer vaccine product pipeline has substantially progressed from the early clinical trial stage (phase I or II) to a more mature phase.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the Developments in Cancer Vaccine Industry, then send an email to Melina Trevino, Corporate Communications, at mtrevino_ti[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you via email.

"Among the notable innovations, Cell Genesys Inc., a biotechnology firm headquartered in South San Francisco, CA, who have currently developed a novel immunotherapeutic approach that incites remarkable optimism to yield an optimal and potent antitumor response," notes Frost & Sullivan Technical Insights Research Analyst Vanitha S.V. "The company's cancer immunotherapy platform, GVAX cancer immunotherapy, is a novel non-patient-specific, off-the-shelf, cell-based therapy consisting of one or more established tumor cell lines."

Employing whole tumor cells in the GVAX platform, one of the key benefits, offers a significant advantage of presenting the patient's immune system to a broad spectrum of multiple tumor cell components or antigens. This could potentially result in an immune response significantly broader than if obtained by presenting just one or a few tumor antigens.

Notwithstanding such innovations, the industry faces challenges related to the clinical development paradigms for cancer vaccines, which follow the pathways designed for conventional cytotoxic drugs. As cancer vaccines subside in a different class of complex biological compounds, significant distinctions do exist in their clinical activity.

"Given this, clinical trial designs and study endpoints should select as if catering to the unique characteristics of cancer vaccines," says Vanitha. "Apart from this, we must substantiate the importance of addressing the potential use of cancer vaccines to treat patients at earlier stages of disease. Hence, clinical studies will involve a subset of patient population that inhabit in a disease stage at which they can obtain maximum benefits."

As we move forward, the importance of adopting a more focused and flexible development pathway should address the unique features of cancer vaccines. Active collaborations would also play a major role as they could draw substantial investments from large pharmas toward developing and commercialization of cancer vaccine products. A single approved product in the market could well do wonders for the industry, engendering renewed hope and enthusiasm for cancer vaccine industry.

Developments in Cancer Vaccine Industry, a part of the Technical Insights Growth Partnership Services program, provides analyzes the latest developments in the cancer vaccine field, both from a technology and industry perspective. An in-depth assessment of the therapeutic cancer vaccine industry is provided, inclusive of the technology and industry drivers, challenges and barriers that impact the growth and commercialization of the industry. The study seeks to strategically evaluate the competitive environment by providing a comprehensive insight of therapeutic cancer vaccine products and their developers. Interviews with the press are available.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Developments in Cancer Vaccine Industry
D0CD

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Robust New Technology Platforms Aid the Search for Cancer Vaccines

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Rapid Recovery

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)